The effect of azithromycin on the immunogenicity of oral poliovirus vaccine: a double-blind randomised placebo-controlled trial in seronegative Indian infants

The Lancet Infectious Diseases

Volumn 16, Issue 8, 2016, Pages 905-914

  Grassly, Nicholas C ^a,b   Praharaj, Ira ^b   Babji, Sudhir ^b   Kaliappan, Saravanakumar Puthupalayam ^b   Giri, Sidhartha ^b   Venugopal, Srinivasan ^b   Parker, Edward P K ^a   Abraham, Asha ^b   Muliyil, Jayaprakash ^b   Doss, Sridhar ^b   Raman, Uma ^b   Liu, Jie ^c   Peter, John Victor ^b   Paranjape, Meghana ^b   Jeyapaul, Shalini ^b   Balakumar, Shailaja ^b   Ravikumar, Jeniffer ^b   Srinivasan, Rajan ^b   Bahl, Sunil ^d   Iturriza Gómara, Miren ^e   Uhlig, Holm H ^f   Houpt, Eric R ^c   John, Jacob ^b   Kang, Gagandeep ^b   more..

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CHRISTIAN MEDICAL COLLEGE   (India)

^c UNIVERSITY OF VIRGINIA   (United States)

^d WHO Regional Office for South East Asia   (India)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; AZITHROMYCIN; MYELOPEROXIDASE; NEUTRALIZING ANTIBODY; PLACEBO; POLIOMYELITIS VACCINE; ANTIINFECTIVE AGENT; ORAL POLIOMYELITIS VACCINE; VIRUS ANTIBODY;

ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; IMMUNOGENICITY; INDIAN; INFANT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VIRUS VIRULENCE; BLOOD; IMMUNIZATION; IMMUNOLOGY; INDIA; POLIOMYELITIS; POLIOMYELITIS VIRUS; PROCEDURES; VACCINATION; VACCINE IMMUNOGENICITY;

ANTI-BACTERIAL AGENTS; ANTIBODIES, VIRAL; AZITHROMYCIN; DOUBLE-BLIND METHOD; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGENICITY, VACCINE; INDIA; INFANT; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; VACCINATION;

EID: 84964961679     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30023-8     Document Type: Article

References (30)

1. 1 Qadri, F, Bhuiyan, TR, Sack, DA, Svennerholm, AM, Immune responses and protection in children in developing countries induced by oral vaccines. Vaccine 31 (2013), 452–460.
2. 2 Levine, MM, Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol, 8, 2010, 129.
3. 3 Grassly, NC, Fraser, C, Wenger, J, et al. New strategies for the elimination of polio from India. Science 314 (2006), 1150–1153.
4. 4 O'Reilly, KM, Durry, E, ul Islam, O, et al. The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001–11: a retrospective analysis. Lancet 380 (2012), 491–498.
5. 5 Sabin, AB, Michaels, RH, Krugman, S, Eiger, ME, Berman, PH, Warren, J, Effect of oral poliovirus vaccine in newborn children: I. Excretion of virus after ingestion of large doses of type I or of mixture of all three types, in relation to level of placentally transmitted antibody. Pediatrics 31 (1963), 623–640.
6. 6 Appaiahgari, MB, Glass, R, Singh, S, et al. Transplacental rotavirus IgG interferes with immune response to live oral rotavirus vaccine ORV-116E in Indian infants. Vaccine 32 (2014), 651–656.
7. 7 Parker, EPK, Kampmann, B, Kang, G, Grassly, NC, Influence of enteric infections on response to oral poliovirus vaccine: a systematic review and meta-analysis. J Infect Dis 210 (2014), 853–864.
8. 8 Kotloff, KL, Nataro, JP, Blackwelder, WC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 382 (2013), 209–222.
9. 9 World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. Factors affecting the immunogenicity of oral poliovirus vaccine–a prospective evaluation in Brazil and the Gambia. J Infect Dis 171 (1995), 1097–1106.
10. 10 Maldonado, YA, PenaCruz, V, Sanchez, MD, et al. Host and viral factors affecting the decreased immunogenicity of Sabin type 3 vaccine after administration of trivalent oral polio vaccine to rural Mayan children. J Infect Dis 175 (1997), 545–553.
11. 11 Kau, AL, Planer, JD, Liu, J, et al. Functional characterization of IgA-targeted bacterial taxa from undernourished Malawian children that produce diet-dependent enteropathy. Sci Transl Med, 7, 2015, 276ra24.
12. 12 Kelly, P, Menzies, I, Crane, R, et al. Responses of small intestinal architecture and function over time to environmental factors in a tropical population. Am J Trop Med Hyg 70 (2004), 412–419.
13. 13 Korpe, PS, Petri, WA, Environmental enteropathy: critical implications of a poorly understood condition. Trends Mol Med 18 (2012), 328–336.
14. 14 Keusch, GT, Denno, DM, Black, RE, et al. Environmental enteric dysfunction: pathogenesis, diagnosis, and clinical consequences. Clin Infect Dis 59:suppl 4 (2014), S207–S212.
15. 15 Kosek, M, Hague, R, Lima, A, et al. Fecal markers of intestinal inflammation and permeability associated with the subsequent acquisition of linear growth deficits in infants. Am J Trop Med Hyg 88 (2013), 390–396.
16. 16 Naylor, C, Lu, M, Haque, R, et al. Environmental enteropathy, oral vaccine failure and growth faltering in infants in Bangladesh. EBioMedicine 2 (2015), 1759–1766.
17. 17 Lode, H, Borner, K, Koeppe, P, Schaberg, T, Azithromycin—review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother 37 (1996), 1–8.
18. 18 Shinkai, M, Henke, MO, Rubin, BK, Macrolide antibiotics as immunomodulatory medications: Proposed mechanisms of action. Pharmacol Ther 117 (2008), 393–405.
19. 19 Praharaj, I, John, SM, Bandyopadhyay, R, Kang, G, Probiotics, antibiotics and the immune responses to vaccines. Philos Trans R Soc B Biol Sci, 370, 2015, 12.
20. 20 WHO. Manual of laboratory methods for testing of vaccines used in the WHO expanded programme on immunization. WHO/VSQ/97.04. http://apps.who.int/iris/bitstream/10665/63576/1/WHO_VSQ_97.04_(parts1-2).pdf, 1997 (accessed April 27, 2016).
21. 21 Liu, J, Kabir, F, Manneh, J, et al. Development and assessment of molecular diagnostic tests for 15 enteropathogens causing childhood diarrhoea: a multicentre study. Lancet Infect Dis 14 (2014), 716–724.
22. 22 Caceres, VM, Sutter, RW, Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clin Infect Dis 33 (2001), 531–541.
23. 23 Patel, M, Steele, AD, Parashar, UD, Influence of oral polio vaccines on performance of the monovalent and pentavalent rotavirus vaccines. Vaccine 30 (2012), A30–A35.
24. 24 Wang, HP, Moon, S, Wang, YH, Jiang, BM, Multiple virus infection alters rotavirus replication and expression of cytokines and Toll-like receptors in intestinal epithelial cells. Virus Res 167 (2012), 48–55.
25. 25 Lin, JF, Chen, JM, Zuo, JH, et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis 20 (2014), 1407–1415.
26. 26 Lundell, AC, Adlerberth, I, Lindberg, E, et al. Increased levels of circulating soluble CD14 but not CD83 in infants are associated with early intestinal colonization with Staphylococcus aureus. Clin Exp Allergy 37 (2007), 62–71.
27. 27 Prendergast, AJ, Rukobo, S, Chasekwa, B, et al. Stunting is characterized by chronic inflammation in Zimbabwean infants. PLoS One, 2014 published online Feb 18. DOI:10.1371/journal.pone.0086928.
28. 28 Trehan, I, Shulman, RJ, Ou, CN, Maleta, K, Manary, MJ, A randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in the treatment of tropical enteropathy. Am J Gastroenterol 104 (2009), 2326–2333.
29. 29 Gough, EK, Moodie, EEM, Prendergast, AJ, et al. The impact of antibiotics on growth in children in low and middle income countries: systematic review and meta-analysis of randomised controlled trials. BMJ, 348, 2014, g2267.
30. 30 Liu, J, Gratz, J, Amour, C, et al. A laboratory developed TaqMan array card for simultaneous detection of nineteen enteropathogens. J Clin Microbiol 51 (2012), 472–480.